A Phase I, multicenter, open-label, adaptive design, dose-escalation study of KK8123 in adult patients with X-linked hypophosphatemia
- Study HIC#:2000037697
- Last Updated:02/26/2025
The purpose of this research study is to determine the safety and effectiveness of a new treatment for adults with XLH. The study medication is called KK8123 and is expected to help improve blood phosphorus levels and thereby improve the symptoms of XLH.
Contact Us
For more information about this study, including how to volunteer, contact:
Elizabeth Olear
- Phone Number: 1-203-785-6779
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
To participate, you must have a diagnosis of X-linked hypophosphatemia (XLH) and be between 18-65 years of age, not currently taking active therapy (Crysvita®(burosumab) or phosphate and/or calcitriol); if you have taken burosumab in the past you must discontinued it for 7 months prior to the Screening Visit for this study, if you are on supplemental phosphorus and/or calcitriol (prescription Vitamin D) you must discontinue for 14 days prior to the Screening Visit.
